288.
Filimonov, D.A
. QNA based “Star Track” QSAR approach [Текст]/
D.A. Filimonov, A.V. Zakharov, A.A. Lagunin [et al.]// SAR and QSAR in
Environmental Research. – 2009. – V. 20, №7–8. – р. 679–709.
289.
Filz, O.A
. Fragment–based lead design [Текст]/ O.A. Filz, V.V. Poroikov
// Russian Chemical Reviews. – 2012. – V. 81, №2. – р. 158–174.
290.
Fourches, D
. Сomputational Tools for ADMET Profiling / Computational
Toxicology: Risk Assessment for Chemicals [Текст] / D. Fourches, A.J. Williams
G. Patlewicz // John Wiley & Sons, Inc. – 2018. – р. 211–244.
291.
Franke, R
. Theoretical Drug Design Methods [Текст]: R. Franke. –
Berlin: Akademie-Verlag, 1984. – p. 382–391.
292.
Free, S.M
. A mathematical contribution to structure–activity
studies
[Текст] / S.M. Free, J.W. Wilson // Journal of Medicinal Chemistry. – 1964. –
№7. – р. 395–399.
293.
Fu, D.Y
. Predictive Power of different types of experimental restraints
in small molecule docking: A review [Текст] / D.Y. Fu, J. Meiler // Journal of
Chemical Information and Modeling. – 2018. – V. 58, №2. – р. 225–233.
294.
Gasteiger, J
. Chemoinformatics: Achievements and Challenges, a
Personal View [Текст] / J. Gasteiger // Molecules. – 2016. – V. 21, №2. – 151 р.
295.
Gasteiger, J
. Handbooks of Cheminformatics: From Data to Knowledge
[Текст] / J. Gasteiger. – Weinheim: Wiley–VCH, 2003. – №4. – 1930 р.
296.
Gao, Y
. Effects of centrally acting ACE inhibitors on the rate of cognitive
decline in dementia [Текст] / Y. Gao, R. O’Caoimh, L. Healy [et al.] // BMJ
Open. –2013. – № 3. – р. 1–8.
297.
Gea, H
. Synchronized dynamics and non-equilibrium steady states in a
stochastic yeast cell-cycle network / H. Gea, H. Qian, M. Qian // Mathematical
Biosciences. – 2008. – V. 211. – р. 132–152.
298.
Geronikaki, A
. Computer-aided predictions for medicinal chemistry via
Internet [Текст] / A. Geronikaki, D. Druzhilovsky, A. Zakharov [et al.] // SAR
and QSAR in Environmental Research. – 2008. – V. 19, №1–2. – р. 27–38.
299.
Geronikaki, A
. Design of new anxiolytics: from computer prediction to
synthesis and biological evaluation / A. Geronikaki, E. Babaev, J. Dearden [et al.]
// Bioorganic & Medicinal Chemistry. – 2004. – V. 12, №24. – p. 6559–6568.
300.
Ghose, A.K
. A knowledge-based approach in designing combinatorial
or medicinal chemistry libraries for drug discovery. 1. Aqualitative and
quantitative characterization of known drug databases [Текст] / A.K. Ghose,
V.N. Viswanadhan, J.J. Wendoloski // Journal of Combinatorial Chemistry. –
1999. – V. 1, №1. – р. 55–68.
301.
Gillbro, J.M
. Structural activity relationship analysis (SAR) and in vitro
testing reveal the anti-ageing potential activity of acetyl aspartic acid [Текст] /
J.M. Gillbro, M. Lundahl, M. Westman [et al.] // International Journal of Cosmetic
Science. – 2015. – V. 37, №S.1. – р. 15–20.
302.
Goel, R.K
. Pharmacological repositioning of Achyranthes aspera as
antidepressant using pharmacoinformatic tools PASS and PharmaExpert: A case
study with wet lab validation / R.K. Goel, D.Y. Gawande, A.A. Lagunin [et al.]//
SAR and QSAR in Environmental Research. – 2018. –V. 29, №1. – p. 69–81.
303.
Graur, D
. Phylogenetic position of the order Lagomorpha (rabbits, hares
and allies) [Текст] / D. Graur, L. Duret, M. Gouy // Nature. – 1996. – 379 p.
Список литературы
377
304. GRID-GOLPE (Graphic Retrieval and Information Display – General
Optimal Linear PLS Estimation) [Электронный ресурс]. – Режим доступа:
https://www.allacronyms.com/GRID/Graphic_Retrieval_and_Information_
Display.
305.
Grob, A
. Representing dynamic biological networks with multi–scale
probabilistic models [Электронный ресурс]/ A. Grob, B. Kracher, J.M. Kraus
[et al.] // Communications Biology. – 2019. – V. 2, №21. – Режим доступа:
www.nature.com/articles/s42003-018-0268-3.
306.
Gross, G
. Strategies for Enhancing Oral Bioavailability and Brain
Penetration [Текст]: In: The Practice
of Medicinal Chemistry, Fourth edition.
Wermuth C.G., Aldous D., Raboisson R., Rognan D., Eds. / G. Gross. –
Amsterdam: Academic Press, 2015. – p. 631–655.
307.
Groussin, L
. Loss of Expression of the Ubiquitous Transcription
Factor cAMP Response Element-Binding Protein (CREB) and Compensatory
Overexpression of the Activator CREMτ in the Human Adrenocortical Cancer
Cell Line H295R [Текст] / L. Groussin, J. F. Massias, X. Bertagna [et al.]// The
Journal of Clinical Endocrinology & Metabolism. – V. 85, №1. – р. 345–354.
308. Guidance for Industry. Bioanalytical Method Validation [Электронный
ресурс]// Food and Drug administration. – 2013. – Режим доступа: http://www.
fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/
ucm368107.
309. Guidance for Industry. Bioequivalence Studies with Pharmacokinetic
Endpoints for Drugs Submitted Under an ANDA [Электронный ресурс]//
Food and Drug administration. – 2013. – Режим доступа: https://www.fda.gov/
downloads/drugs/guidances/ucm377465.pdf.
310. Guidance for Industry. Dissolution Testing of Immediate Release Solid
Oral Dosage Forms [Электронный ресурс]// Food and Drug administration. –
1997. – Режим доступа: http://www.fda.gov/downloads/Drugs/... /Guidances/
ucm070237.pdf.
311. Guidance for Industry. E16 Biomarkers Related to Drug or Biotechnology
Product Development: Context,
Structure, and Format of Qualification
Submissions [Электронный ресурс]// Food and Drug Administration. – 2011. –
Режим доступа: https://www.fda.gov/media/81311/download.
312. Guidance for Industry. ICH M4. Оrganization of the CTD [Электрон-
ный ресурс] // U. S. Department of Health and Human Services Food and Drug
Administration. Center for Drug Evaluation and Research (CDER). Center for
Biologies Evaluation and Research (CBER). – 2001. – Режим доступа: https://
www.fda.gov/media/71551/download.
313. Guidance for Industry. SUPAC–IR: Immediate–Release Solid Oral
Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing
and
Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence
Documentation [Электронный ресурс] // US FDA, CDER. – 1995. – Режим
доступа: www.fda.gov/regulatory-information/search-fda-guidance-documents/
supac-ir-immediate-release-solid-oral-dosage-forms-scale-and-post-approval-
changes-chemistry.
314. Guidance for Industry. SUPAC-MR: Modified Release Solid Oral Dosage
Forms [Электронный ресурс]// Food and Drug administration. – 1997. – Режим
378
Достарыңызбен бөлісу: